AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug

Health insurer Highmark inked an outcomes-based contract with AstraZeneca (NYSE:AZN) for Symbicort, the pharmaceutical company’s drug designed to treat asthma and chronic obstructive pulmonary disease. Highmark said its contract with AstraZeneca is one of the first outcomes-based deals involving a respiratory drug and will apply to commercial members of its national and core markets in Pennsylvania, West Virginia and Delaware. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat AstraZeneca plc Source Type: news

Related Links:

Heart rate variability (HRV) biofeedback is a simple and noninvasive method for brain stimulation. This method includes paced breathing at a rate of about 6 breaths per minute (0.1Hz), which is slower and more rhythmical than natural breathing. HRV biofeedback has been used to successfully treat a wide spectrum of diseases, such as asthma, COPD, IBS, fibromyalgia, hypertension, depression, anxiety, PTSD, and insomnia (Gevirtz, 2013). It has been employed to improve performance in athletes and human operators.
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - Category: Neurology Authors: Source Type: research
Asthma UK figures suggest life threatening attack happens as frequently as every three seconds Related items fromOnMedica Worse asthma control linked to poor school work Adjuvanted trivalent flu vaccine best option for over-65s Medicines linked to risk of community-acquired pneumonia Three quarters of adult COPD cases may originate in childhood High TV viewing linked to increased asthma risk
Source: OnMedica Latest News - Category: UK Health Source Type: news
Publication date: Available online 15 January 2019Source: Preventive MedicineAuthor(s): Mary L. Adams, Joseph Grandpre, David L. Katz, Douglas ShensonAbstractWe studied associations between 7 cardiovascular disease (CVD) risk factors (RFs) and 9 chronic conditions and estimated population-attributable risk. Data (N = 358,218) were from the 2017 Behavioral Risk Factor Surveillance System. Outcomes included asthma, arthritis, chronic obstructive pulmonary disease (COPD), cognitive impairment, CVD, and kidney disease. Risk factors (RF) were obesity, ever smoking, sedentary lifestyle, and inadequate fruit and vegetable con...
Source: Preventive Medicine - Category: International Medicine & Public Health Source Type: research
CONCLUSION: IL-17A is a major regulator of inflammatory responses. In all the mentioned diseases, IL-17A plays a prime role in inducing the diseases, whereas the lack of this pro-inflammatory cytokine reduces the severity of respective respiratory diseases. Thereby, this review suggests IL-17A as an instrumental target in the chronic respiratory diseases. PMID: 30652654 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Endocrinology Authors: Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Semin Respir Crit Care Med 2018; 39: 667-673 DOI: 10.1055/s-0038-1676571Excessive central airway collapse (ECAC) is characterized by excessive narrowing of the airway lumen during exhalation leading to dyspnea, cough, mucostasis, recurrent respiratory infections, and poor quality of life. Tracheobronchomalacia and excessive dynamic airway collapse are heterogeneous entities of ECAC and are characterized by a diverse nonspecific symptom profile. Although the pathophysiology of airway mechanics as well as morphology in both entities is different, current evidence so far shows no practical benefit in making such distinction s...
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Review Article Source Type: research
Publication date: Available online 10 January 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Richard H. Stanford, Carlyne Averell, Emily D. Parker, Cori Blauer-Peterson, Tyler K. Reinsch, Ami R. BuikemaAbstractBackgroundWhile efficacy and safety of fluticasone furoate/vilanterol (FF/VI) and budesonide/formoterol (BUD/F) have been demonstrated in clinical studies, real-world comparisons of utilization has not been performed.ObjectiveCompare similar asthma patients initiating FF/VI or BUD/F on measures of adherence, persistence, and the asthma medication ratio (AMR).MethodsThis was a retros...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Conclusions: Lung ultrasonography, when complemented with other tools of investigation, aids evaluation, allows for earlier treatment and more accurate disposition of undifferentiated dyspneic patients in the ED. The addition of cardiac ultrasound was not able to reliably differentiate the causes of pulmonary edema. PMID: 30622794 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
In a blog post last week, I shared an excerpt from the new book that Paul Cerrato and I just completed,The Transformative Power of Mobile Medicine. Here is a second excerpt from Chapter 3,  “Exploring the Strengths and Weaknesses of Mobile Health Apps.”Even patients who are fully engaged in their own care still need access to medical apps they can trust. The IQVIA Institute for Human Data Science has performed a detailed analysis of the clinical evidence supporting mobile health apps, rating their maturity and relative quality. Its rating scale places a single observational study near the bottom of th...
Source: Life as a Healthcare CIO - Category: Information Technology Source Type: blogs
We evaluated the relationships between hyperpolarized3He ventilation defect percent (VDP) and respiratory system resistance, reactance andAX oscillometry measurements in 175 participants.R5 ‐19 andX5 demonstrated different relationships with VDP in patients with different disease phenotypes, whereasAX was weakly related to VDP in all subgroups with airflow obstruction. Our results demonstrated thatAX is sensitive to obstruction but not specific to the type of obstruction, and that the different relationships for MRI VDP withR5 ‐19 andX5 may reflect airway and parenchymal disease ‐specific biomechanical abnormalities ...
Source: Physiological Reports - Category: Physiology Authors: Tags: Original Research Source Type: research
Propeller Health today launched a feature within the Propeller mobile app designed to connect users directly with pharmacy services. The Madison, Wis.-based company kicked off the feature with Walgreens, giving Walgreens patients the option to manage their asthma or chronic obstructive pulmonary disease medication regimen within the mobile app. Get the full story at our sister site, Drug Delivery Business News. The post Propeller Health launches in-app pharmacy feature appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Drug-Device Combinations Pharmaceuticals Respiratory Propeller Health Source Type: news
More News: Asthma | AstraZeneca | Chronic Obstructive Pulmonary | Contracts | Insurers | Respiratory Medicine | Symbicort